Sunitinib induced nephrotic syndrome and thrombotic microangiopathy

Mahesha Vankalakunti, PK Jha, Vishwanath Siddini, R. Bonu, G. K. Surya Prakash, K. Ranjith Babu, HS Ballal

Indian Journal of Nephrology · 2013 · 18 citations · 17 references

DOIFull text

Open access

Concepts

Abstract

Sunitinib is an oral, multitargeted receptor tyrosine kinase inhibitor of targets such as vascular endothelial growth factor and platelet derived growth factor receptor. It is used for the treatment of metastatic renal cell carcinoma (RCC). Use of sunitinib has been associated with renal dysfunction and nephrotic syndrome. However, simultaneous occurrence of nephrotic syndrome and renal dysfunction in a patient treated with sunitinib is rare. We report a case of metastatic RCC treated with sunitinib for 22 months who presented with nephrotic syndrome and renal dysfunction. Renal biopsy was diagnostic of thrombotic microangiopathy with diffuse effacement of podocytic foot process.

References

17